Peptide injectors need needle programs and safety advice say Queensland researchers

Four University of Queensland researchers say Australia's peptide injectors need the same safety advice and sterile equipment offered to other people who inject drugs. Writing in The Conversation on October 26, they argue that buyers of online peptides rarely see themselves as drug injectors and so miss basic guidance. Their warning follows a state alert to hospitals on rising hospital presentations linked to unapproved peptides. The authors call for more funding for needle and syringe programs, which they say are already stretched by the new demand.

What the Queensland researchers found

The article is by Kimberley Akrigg, Jason Ferris, Samuel Cornell and Timothy Piatkowski, all of the University of Queensland, and it appeared in The Conversation as a commentary rather than a new study. The authors describe a group of people who order peptide vials online for muscle gain, weight loss, recovery from training, skin or sleep. Such packages often arrive with a few syringes and no leaflet, they write, so buyers learn from forums, influencers or friends at the gym. That differs from a patient prescribed an approved weight loss injection by a doctor, who is shown how to inject, given a sharps container and told which signs of infection to watch for. The authors list reused needles, poor hygiene and missed early infections among the mistakes being reported.

The researchers point to hospital data as evidence that harm is already occurring. Citing reporting by The Sydney Morning Herald, they write that peptide related hospitalisations in New South Wales rose from five in July 2025 to more than 200 in September 2026. That figure comes from newspaper coverage of state data, and the full dataset has not been published. Piatkowski discloses that he is vice chair of Queensland Injectors Voice for Advocacy and Action and a co-founder of a harm reduction charity, and he sits on a performance enhancement task force for the Enhanced Games. Ferris lists public research funding. Akrigg and Cornell declare no relevant affiliations. The authors do not claim any product is safe, and they stress that online peptides are not tested like medicines.

NSW Health warns clinicians about unapproved peptides

NSW Health issued Safety Information 009/26 to hospitals on October 15, 2026, reporting an increase in presentations associated with unapproved peptide products. The NSW Health safety notice asks clinicians to consider peptide use in patients with intractable vomiting, skin infections where people injected, unexplained acute pancreatitis or unexplained acute liver injury. It names BPC 157, TB 500, retatrutide, CJC 1295, ipamorelin, Melanotan II and some compounded forms of semaglutide and tirzepatide as products now treated as unapproved. Retatrutide is still in clinical trials and is not registered in Australia. The notice says such products may contain the wrong ingredient, the wrong strength, contaminants or none of the advertised drug, and they may not be sterile.

NSW Health issued Safety Information 009/26 to hospitals on October 15, 2026, reporting an increase in presentations associated with unapproved peptide products.

The notice also gives practical steps for hospital staff. Clinicians are told to ask about peptides when taking a full medication history and to use a non-judgemental approach, because patients may not see their use as risky. People due for anaesthesia should be asked about peptides, since some products can delay stomach emptying and raise the risk of aspiration. Where a patient suffers significant harm, such as needing admission, staff should report it to the state health department and through the adverse event pathway of the Therapeutic Goods Administration. NSW Health adds that a product labelled for research purposes is likely to be both unapproved and unlawful. A product is also suspect if no registered practitioner prescribed it and no Australian pharmacy dispensed it.

Needle and syringe programs under strain

Needle and syringe programs were built to slow the spread of HIV and hepatitis C, and the authors say they now serve a new population. In August, ABC News reported that the Needle Users and AIDS Association in New South Wales was contracted to hand out 500,000 needles and syringes but was distributing up to two million. Its chief executive, Mary Harrod, told the broadcaster that many vending machines at exchange sites were emptied within an hour or two of being refilled. She also described reports of more syringe sharing. In Queensland, Geoff Davey of the Queensland Injectors Health Network told the ABC the rise had been building since the previous year and was a national trend, not a local one.

The pressure lands on services funded for a smaller client base. The authors argue that when sterile equipment runs out, people who inject tend to share it before long, and shared equipment can spread blood borne viruses. They want program budgets set for the number of people now using them rather than the number served years ago. Regulators are moving on the supply side. On September 16, Ahpra and the National Boards published guidance on prescribing off label, unapproved or compounded medicines and said they had acted against practitioners over unsafe prescribing. Medical Board of Australia chair Susan O'Dwyer said "a patient may want peptides, but that doesn't mean they need peptides." The authors note that such moves do not help people who already hold vials at home.

Safety basics for peptide injectors

The authors set out five basics, framed as harm reduction rather than approval of peptide use. First, use a new needle every time, because needles blunt after one use and a used one can carry skin bacteria into the body. Second, never share needles, syringes, vials, the sterile water used to mix powders, swabs or anything else that touches an injection, since blood borne viruses can pass through shared vials. Third, know the signs of infection, such as spreading redness, heat, swelling, pus or fever. Fourth, seek urgent care after a sudden reaction and tell staff what was injected, when and where it came from. Fifth, keep used sharps in a proper container and return it to a program, public sharps bin or pharmacy.

The advice for peptide injectors comes with a wider point about how health information reaches people. The authors write that safety messages must meet buyers online, in gyms and in the places where they buy, because many will never visit a drug service. They say programs in Australia are free and confidential, staff do not ask for names, and carrying equipment obtained from a program is legal. None of this makes an unapproved peptide safer to use. Products sold online have not been assessed for quality, and the NSW notice warns they may hold something other than what the label claims. Similar signals have come from Iceland, where insulin syringe sales climbed and customs tests found vials that did not match their labels.

Conclusion

The Queensland researchers argue that peptide injectors are a real and growing group of people who inject drugs and should be served as one. NSW Health has warned hospitals about related harm, and needle programs report demand far above their contracts. Regulators are tightening prescribing, but the authors say safety advice and equipment are needed now. Our safety desk follows the unapproved peptide market and the response to it.